Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer

BACKGROUND: Improved methods are needed for predicting prognosis and the benefit of delivering adjuvant chemotherapy (ACT) in patients with non-small-cell lung cancer (NSCLC). METHODS: A novel prognostic algorithm was identified using genomic profiles from 332 stage I-III adenocarcinomas and indepen...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Laar, Ryan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407714/
https://www.ncbi.nlm.nih.gov/pubmed/22748043
http://dx.doi.org/10.1186/1755-8794-5-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407714/
https://www.ncbi.nlm.nih.gov/pubmed/22748043
http://dx.doi.org/10.1186/1755-8794-5-30

Ejemplares similares